Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Higher silicone breast implant rupture rate shown in recent data, FDA tells Rep. Shays.

This article was originally published in The Gray Sheet

Executive Summary

SILICONE BREAST IMPLANT RUPTURE RATE APPEARS "SIGNIFICANTLY HIGHER" than previously has been reported, FDA says in a May 25 response to an inquiry from House Government Reform/Human Resources Subcommittee Chairman Christopher Shays (R-Conn.). In a May 10 letter to FDA Commissioner David Kessler, Shays asked the agency to comment on recent clinical studies on the safety of silicone breast implants. Based on a review of recent epidemiological studies, FDA concludes, "There is now data to suggest that the failure rate due to implant rupture may be significantly higher than previously described, and/or may increase significantly with time."
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT004174

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel